---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-26-000011"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T06:53:47.300386+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Halozyme raises 2026 guidance; acquires Surf Bio for $300M upfront

## Summary
- Preliminary 2025 revenue estimated at $1,385-1,400M (+36-38% YoY); royalties $865-870M (+51-52% YoY).
- 2026 revenue guidance raised to $1,710-1,810M (+23-30% YoY) from prior $1,430-1,530M; royalty revenue now >$1B.
- 2026 non-GAAP diluted EPS guidance raised to $7.75-8.25 (prior $6.50-7.00); Adjusted EBITDA $1,125-1,205M.
- Acquired Surf Bio for $300M upfront plus up to $100M milestones; adds hyperconcentration technology for biologics.
- Surf Bio technology enables 500 mg/mL antibody concentrations for single auto-injector subcutaneous delivery.

## SEC filing metadata
- accession: 0001159036-26-000011
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000011/0001159036-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903626000011/halo-20260128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-26-000011
- JSON: https://secwatch.observer/filing/0001159036-26-000011.json
- Plain text: https://secwatch.observer/filing/0001159036-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.